NEW YORK (GenomeWeb News) – MolecularMD said today it is working with drug firm Novartis to develop a companion diagnostic that can help determine which Philadelphia chromosome-positive chronic myeloid leukemia patients have achieved durable minimal residual disease after treatment with Tasigna (nilotinib).

Tasigna is Novartis' next-generation tyrosine kinase inhibitor used to treat patients with newly diagnosed Philadelphia chromosome-positive CML in chronic phase.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.